| Code | CSB-RA012466MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Monalizumab, designed to target KLRC1 (Killer Cell Lectin-like Receptor C1), also known as NKG2A. KLRC1 is an inhibitory receptor expressed on natural killer (NK) cells and subsets of CD8+ T cells that forms heterodimers with CD94. Upon binding to its ligand HLA-E on target cells, KLRC1 delivers inhibitory signals that suppress NK cell and T cell cytotoxicity, representing a key immune checkpoint mechanism exploited by tumor cells and viruses to evade immune surveillance. Dysregulated KLRC1 expression has been implicated in various malignancies and chronic viral infections, making it an important therapeutic target in immuno-oncology.
Monalizumab is a humanized IgG4 monoclonal antibody that blocks the KLRC1/HLA-E interaction, thereby preventing inhibitory signaling and restoring anti-tumor immune responses. This biosimilar antibody serves as a valuable research tool for investigating KLRC1-mediated immune regulation, studying NK cell and T cell biology, and exploring combination immunotherapy strategies in cancer research. It enables researchers to examine checkpoint blockade mechanisms and evaluate potential therapeutic approaches targeting the NKG2A pathway.
There are currently no reviews for this product.